These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28545614)

  • 1. [HERA-QUEST: HTA evaluation of generic pharmaceutical products to improve quality, economic efficiency, patient safety and transparency in drug product changes in hospitals].
    Gyalrong-Steur M; Kellermann A; Bernard R; Berndt G; Bindemann M; Nusser-Rothermundt E; Amann S; Brakebusch M; Brüggmann J; Tydecks E; Müller M; Dörje F; Kochs E; Riedel R
    Z Evid Fortbild Qual Gesundhwes; 2017 Apr; 121():5-13. PubMed ID: 28545614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets.
    Brixner D; Kaló Z; Maniadakis N; Kim K; Wijaya K
    Value Health Reg Issues; 2018 Sep; 16():9-13. PubMed ID: 29605800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets.
    Brixner D; Maniadakis N; Kaló Z; Hu S; Shen J; Wijaya K
    Value Health Reg Issues; 2017 Sep; 13():1-6. PubMed ID: 29073981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of HTA and procurement practices on the selection and prices of medical devices.
    Callea G; Armeni P; Marsilio M; Jommi C; Tarricone R
    Soc Sci Med; 2017 Feb; 174():89-95. PubMed ID: 28013109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospital-based health technology assessment (HTA) in Finland: a case study on collaboration between hospitals and the national HTA unit.
    Halmesmäki E; Pasternack I; Roine R
    Health Res Policy Syst; 2016 Apr; 14():25. PubMed ID: 27044400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug delivery system innovation and Health Technology Assessment: Upgrading from Clinical to Technological Assessment.
    Panzitta M; Bruno G; Giovagnoli S; Mendicino FR; Ricci M
    Int J Pharm; 2015 Nov; 495(2):1005-18. PubMed ID: 26399633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Quality of health care, accreditation, and health technology assessment in Croatia: role of agency for quality and accreditation in health].
    Mittermayer R; Huić M; Mestrović J
    Acta Med Croatica; 2010 Dec; 64(5):425-34. PubMed ID: 21692267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Technology Assessment in Japan: A Pharmaceutical Industry Perspective.
    Kido K; Matsumaru N; Tsukamoto K
    Ther Innov Regul Sci; 2019 Jul; 53(4):472-480. PubMed ID: 30157674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Historical development of health technology assessment in Thailand.
    Teerawattananon Y; Tantivess S; Yothasamut J; Kingkaew P; Chaisiri K
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():241-52. PubMed ID: 19527543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Generic drugs: we must cut pharmaceutical spending but undertaking drug quality].
    Carrillo Norte JA; Postigo Mota S
    Rev Enferm; 2012 Feb; 35(2):10-9. PubMed ID: 22670381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical equivalence by design for generic drugs: modified-release products.
    Raw AS; Lionberger R; Yu LX
    Pharm Res; 2011 Jul; 28(7):1445-53. PubMed ID: 21387150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
    Wong CKH; Wu O; Cheung BMY
    Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Development of the Romanian Scorecard HTA System.
    Radu CP; Chiriac ND; Pravat AM
    Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Generic drugs in the medical-economic context of drug prescriptions].
    Bouvenot G; Villani P; Bouvenot J
    Presse Med; 2002 Jul; 31(24):1109-14. PubMed ID: 12162093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The analogue substitution model: Introducing competition in the absence of generic substitution in Danish hospitals.
    Christensen E; Hirsch NC; Andersen JV; Ehlers LH
    Health Policy; 2022 Sep; 126(9):844-852. PubMed ID: 35728981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New trends and challenges in the European regulation of innovative medicines.
    Enzmann H
    Regul Toxicol Pharmacol; 2016 Oct; 80():314-20. PubMed ID: 27237379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HEALTH TECHNOLOGY ASSESSMENT IN EVALUATION OF PHARMACEUTICALS IN THE CZECH REPUBLIC.
    Vostalová L; Mazelová J; Samek J; Vocelka M
    Int J Technol Assess Health Care; 2017 Jan; 33(3):339-344. PubMed ID: 28438231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.